104 related articles for article (PubMed ID: 19767656)
21. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
Prodanovic EM; Korman NJ
J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187
[TBL] [Abstract][Full Text] [Related]
22. Cladribine in indolent non-Hodgkin's lymphoma.
Sigal DS; Saven A
Expert Rev Anticancer Ther; 2008 Apr; 8(4):535-45. PubMed ID: 18402520
[TBL] [Abstract][Full Text] [Related]
23. Progress in the non-Hodgkin's lymphomas.
Yuen AR
Ann Oncol; 1999; 10 Suppl 6():19-22. PubMed ID: 10676549
[No Abstract] [Full Text] [Related]
24. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
25. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
26. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
27. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
[No Abstract] [Full Text] [Related]
28. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
30. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
[No Abstract] [Full Text] [Related]
31. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
[TBL] [Abstract][Full Text] [Related]
32. A revolution in the treatment of non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Oldham RK; DeNardo SJ
Cancer Biother Radiopharm; 1998 Aug; 13(4):213-23. PubMed ID: 10850358
[TBL] [Abstract][Full Text] [Related]
33. Treatment approaches and nursing considerations for non-Hodgkin's lymphoma.
Long J; Versea L
Semin Oncol Nurs; 2006 May; 22(2):97-106. PubMed ID: 16720232
[TBL] [Abstract][Full Text] [Related]
34. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.
Friedberg JW; Freedman AS
Curr Treat Options Oncol; 2006 Jul; 7(4):276-84. PubMed ID: 16916488
[TBL] [Abstract][Full Text] [Related]
35. Iodine-131 Tositumomab(Bexxar) in relapsed/refractory non-Hodgkin's lymphoma: update from the 2001 American Society of Hematology meeting.
Gibson A
Clin Lymphoma; 2002 Mar; 2(4):209-11. PubMed ID: 11970759
[No Abstract] [Full Text] [Related]
36. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
Kaminski MS; Armitage JO
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-54-8. PubMed ID: 23570101
[No Abstract] [Full Text] [Related]
37. Review of antibody-based immunotherapy in the treatment of non-Hodgkin lymphoma and patterns of use.
Cannon AC; Loberiza FR
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):129-38. PubMed ID: 25176473
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibody therapy and non-Hodgkin's lymphoma.
Goldstein MR; Mascitelli L; Pezzetta F
N Engl J Med; 2009 Jan; 360(2):192; author reply 193. PubMed ID: 19129537
[No Abstract] [Full Text] [Related]
39. Immunotherapy: a novel treatment for Non-Hodgkin's lymphoma.
Hohenstein M
Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):10-5. PubMed ID: 11878046
[TBL] [Abstract][Full Text] [Related]
40. It's a targeted world in non-Hodgkin's lymphoma.
Okosun J; Fitzgibbon J
Br J Nurs; 2011 Sep 22-Oct 13; 20(17):S28. PubMed ID: 22067535
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
